LNTH Stock Analysis: Lantheus Holdings | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 6.644m USD | 12M Return: 90.7% | US5165441032 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 90.6M
EPS Trend: -78.2%
Qual. Beats: 4
Rev. Trend: 83.1%
Qual. Beats: 5
Warnings
No concerns identified
Tailwinds
Seasonality 11.4 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Lantheus Holdings (NASDAQ: LNTH) develops, manufactures, and sells medical imaging and treatment products for cardiovascular disease, cancer, and other conditions. Its marketed portfolio includes ultrasound and nuclear medicine imaging agents, including DEFINITY and PYLARIFY, as well as RELISTOR for opioid-induced constipation. The company also develops radiopharmaceutical therapies and diagnostic agents, including candidates for prostate cancer and neuroendocrine tumors.
Radiopharmaceuticals use radioactive substances to help image disease or deliver targeted treatment. Lantheus is based in Bedford, Massachusetts, and collaborates with companies including GE HealthCare and Curium Pharma.
- PYLARIFY sales growth faces expanding PSMA PET competition
- PNT2002 regulatory progress could unlock radioligand therapy revenue
- DEFINITY demand and radiopharmaceutical supply drive imaging revenue
| Net Income: 269.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -1.84 > 1.0 |
| NWC/Revenue: 49.78% < 20% (prev 37.90%; Δ 11.89% < -1%) |
| CFO/TA 0.17 > 3% & CFO 409.5m > Net Income 269.9m |
| Net Debt (-59.3m) to EBITDA (453.1m): -0.13 < 3 |
| Current Ratio: 3.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.4m) vs 12m ago 1.11% < -2% |
| Gross Margin: 61.26% > 18% (prev 62.23%; Δ -0.97% > 0.5%) |
| Asset Turnover: 66.02% > 50% (prev 67.03%; Δ -1.01% > 0%) |
| Interest Coverage Ratio: 18.29 > 6 (EBIT TTM 362.2m / Interest Expense TTM 19.8m) |
| A: 0.32 (Total Current Assets 1.12b - Total Current Liabilities 346.0m) / Total Assets 2.46b |
| B: 0.36 (Retained Earnings 895.3m / Total Assets 2.46b) |
| C: 0.15 (EBIT TTM 362.2m / Avg Total Assets 2.37b) |
| D: 1.23 (Book Value of Equity 1.36b / Total Liabilities 1.10b) |
| Altman-Z'' = 5.59 = AAA |
| DSRI: 0.88 (Receivables 345.7m/383.3m, Revenue 1.56b/1.53b) |
| GMI: 1.02 (GM 62.23% / 61.26%) |
| AQI: 0.92 (AQ_t 0.48 / AQ_t-1 0.52) |
| SGI: 1.02 (Revenue 1.56b / 1.53b) |
| TATA: -0.06 (NI 269.9m - CFO 409.5m) / TA 2.46b) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of November 19, 2026, the stock is trading at USD 102.00 with a total of 946,774 shares traded. Over the past week, the price has changed by +0.39%, over one month by +2.08%, over three months by +1.74% and over the past year by +90.65%.
Current recommended Stop Loss: 101.40 (which is 0.6% or 1.3 ATR below the current price).
Lantheus Holdings has received a consensus analysts rating of 3.11. Therefore, it is recommended to hold LNTH.
- StrongBuy: 0
- Buy: 1
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 106 | 3.9% |
P/E Trailing = 25.2711
P/E Forward = 14.4509
P/S = 4.253
P/B = 4.8844
P/EG = 0.61
Revenue TTM = 1.56b USD
EBIT TTM = 362.2m USD
EBITDA TTM = 453.1m USD
Long Term Debt = 571.1m USD (from longTermDebt, last quarter)
Short Term Debt = 605k USD (from shortTermDebt, last quarter)
Debt = 624.3m USD (corrected: LT Debt 571.1m + ST Debt 605k) + Leases 52.5m
Net Debt = -59.3m USD (calculated: Debt 624.3m - CCE 683.6m)
Enterprise Value = 6.58b USD (6.64b + Debt 624.3m - CCE 683.6m)
Interest Coverage Ratio = 18.29 (Ebit TTM 362.2m / Interest Expense TTM 19.8m)
EV/FCF = 16.75x (Enterprise Value 6.58b / FCF TTM 393.1m)
FCF Yield = 5.97% (FCF TTM 393.1m / Enterprise Value 6.58b)
FCF Margin = 25.16% (FCF TTM 393.1m / Revenue TTM 1.56b)
Net Margin = 17.28% (Net Income TTM 269.9m / Revenue TTM 1.56b)
Gross Margin = 61.26% ((Revenue TTM 1.56b - Cost of Revenue TTM 605.1m) / Revenue TTM)
Gross Margin QoQ = 62.43% (prev 62.30%)
Tobins Q-Ratio = 2.68 (Enterprise Value 6.58b / Total Assets 2.46b)
Interest Expense / Debt = 3.17% (Interest Expense 19.8m / Debt 624.3m)
Taxrate = 21.17% (72.5m / 342.4m)
NOPAT = 285.5m (EBIT 362.2m * (1 - 21.17%))
Current Ratio = 3.25 (Total Current Assets 1.12b / Total Current Liabilities 346.0m)
Debt / Equity = 0.46 (Debt 624.3m / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = -0.13 (Net Debt -59.3m / EBITDA 453.1m)
Debt / FCF = -0.15 (Net Debt -59.3m / FCF TTM 393.1m)
Total Stockholder Equity = 1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.41% (Net Income 269.9m / Total Assets 2.46b)
RoE = 21.72% (Net Income TTM 269.9m / Total Stockholder Equity 1.24b)
RoCE = 19.97% (EBIT 362.2m / Capital Employed (Equity 1.24b + L.T.Debt 571.1m))
RoIC = 14.05% (NOPAT 285.5m / Invested Capital 2.03b)
WACC = 5.79% (E(6.64b)/V(7.27b) * Re(6.10%) + D(624.3m)/V(7.27b) * Rd(3.17%) * (1-Tc(0.21)))
Discount Rate = 6.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.90 | Cagr: -1.39%
[DCF] Terminal Value 74.99% ; FCFF base≈398.4m ; Y1≈389.2m ; Y5≈390.2m
[DCF] Fair Price = 94.25 (EV 6.10b - Net Debt -59.3m = Equity 6.16b / Shares 65.4m; r=8.35% [WACC [floored]]; 5y FCF grow -3.25% → 2.50% )
EPS Correlation: -78.21 | EPS CAGR: -6.51% | SUE: 1.99 | # QB: 4
Revenue Correlation: 83.07 | Revenue CAGR: 5.54% | SUE: 2.00 | # QB: 5
EPS current Quarter (2027-03-31): EPS=1.58 | Chg30d=+3.95% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=6.19 | Chg30d=+10.54% | Revisions=+25% | GrowthEPS=+1.8% | GrowthRev=+0.4%
EPS next Year (2027-12-31): EPS=6.59 | Chg30d=+3.30% | Revisions=+25% | GrowthEPS=+6.4% | GrowthRev=+8.2%
[Analyst] Revisions Ratio: +50% (up=3, down=0)